Trial Profile
Pharmacokinetics and pharmacogenomics study with erlotinib in the treatment of advanced non-small cell lung cancer (NSCLC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2013
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- 08 Jun 2013 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan record.
- 03 Nov 2011 New trial record